external radiotherapy, somatostatin analogues, CVD chemotherapy, therapeutic doses of high-specific activity [131][I]meta-iodobenzylguanidine, peptide receptor radiotherapy, and molecular targeted drug therapy) based on clinical findings, such as assessment of the rate of tumour progression, biochemical phenotypes, nuclear imaging findings, and germline genetic testing-based molecular clusters.[6,15] The establishment of multidisciplinary teams in specialised centres for determining individualised treatment strategies and the development of more effective novel molecular targeted drugs according to the methods meticulously established by the FIRSTMAPPP trial are eagerly awaited.

*Mitsuhide Naruse, William F Young Jr
mtsnaruse@gmail.com

Endocrine Center and Clinical Research Center, Ijinkai Takeda General Hospital, Kyoto 601-1495, Japan (MN); Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine and Science, Rochester, MN, USA (WFY)

1   Mete O, Asa SL, Gill AJ, et al. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. *Endocr Pathol* 2022; **33:** 90–114.
2   Mayo CH. Paroxysmal hypertension with tumor of retroperitoneal nerve. *JAMA* 1927; **89:** 1047–50.
3   Saegesser F. César Roux (1857–1934) and his times. *Rev Med Suisse Romande* 1984; **104:** 403–64 (in French).
4   Neumann HPH, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. *N Engl J Med* 2002; **346:** 1459–66.
5   Hamidi O, Young WF Jr, Iñiguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. *J Clin Endocrinol Metab* 2017; **102:** 3296–305.
6   Young WF. Metastatic pheochromocytoma: in search of a cure. *Endocrinology* 2020; **161:** bqz019.
7   Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. *Ann Intern Med* 1988; **109:** 267–73.
8   Naruse M, Satoh F, Tanabe A, et al. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan. *Endocr J* 2018; **65:** 359–71.
9   Pryma DA, Chin BB, Noto RB, et al. Efficacy and safety of high-specific-activity ^{131}I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. *J Nucl Med* 2019; **60:** 623–30.
10   Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. *J Clin Endocrinol Metab* 2017; **102:** 3278–87.
11   Ayala-Ramirez M, Chougnet CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. *J Clin Endocrinol Metab* 2012; **97:** 4040–50.
12   O'Kane GM, Ezzat S, Joshua AM, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. *Br J Cancer* 2019; **120:** 1113–19.
13   Baudin E, Goichot B, Berruti A, et al. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet* 2024; published online Feb 22. https://doi.org/10.1016/S0140-6736(23)02554-0.
14   Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. *N Engl J Med* 2012; **366:** 2189–97.
15   Nölting S, Bechmann N, Taieb D, et al. Personalized management of pheochromocytoma and paraganglioma. *Endocr Rev* 2022; **43:** 199–239.

Accelerating the progress of low birthweight reduction

Low birthweight (LBW) is associated with multiple adverse effects including neonatal mortality, growth and development retardation, and higher risk of chronic diseases in adulthood, such as hypertension, cardiovascular diseases, and type 2 diabetes.[1] A 30% reduction in LBW between 2012 and 2030 is one of the Global Nutrition Targets, and achieving this target could also aid progress towards other Sustainable Development Goals (SDGs), including those relating to neonatal mortality and SDG2 to eliminate malnutrition.

In this issue of *The Lancet*, Yemisrach B Okwaraji and colleagues[2] urge the acceleration of progress in LBW reduction to achieve this global target. They report that global LBW estimates for 2020 are about 19·8 million (95% credible interval 18·4–21·7 million), equivalent to 14·7% (13·7–16·1) of liveborn newborns at that time.[2] Almost three-quarters of these LBW newborns were born in southern Asia (44·5%) and sub-Saharan Africa (27·1%). Around two-thirds of LBW newborns were in the 2000 g to less than 2500 g subcategory within northern America, Australia and New Zealand, central Asia, and Europe. The estimated average annual rate of reduction (AARR) was 0·3% per year between 2012 and 2020 worldwide, which is much lower than required to achieve the 2030 target.[2]

The key strength of the study by Okwaraji and colleagues[2] is that 2042 administrative and survey datapoints for LBW prevalence were systematically collected from 158 (81%) of 195 countries and areas worldwide, covering 75% of global livebirths with LBW

data. A Bayesian method is applied to model the LBW trend from 2000 to 2020, which maximises the use of the available data and accounts for regional variation and data quality bias. Additionally, for the first time to our knowledge, LBW is reported by subcategory within northern America, Australia and New Zealand, central Asia, and Europe.

The study also has some limitations.[2] The availability of LBW data could affect the trend estimates. Administrative source data were available for 113 countries and areas, household survey data were identified for 95 countries and areas, and no data on LBW were available for 37 countries and areas. Data source and quality could also introduce bias into the LBW estimates.

Improving the quality of LBW estimates in the future will require strengthening routine data collection systems, increasing the facility birth rate, supplying and using standardised electronic scales, and training health-care workers to measure and record birthweight correctly.[1,3] Improving health information systems is also important to minimise recall bias and to increase the quantity of individual-level data available for estimating the LBW prevalence. Either low-quality birthweight records or recalled birthweight could show data heaping, especially for birthweights of 2500 g, which could have a direct effect on the estimation of LBW prevalence. Adjusting for data heaping would be more appropriate for estimating LBW in such a situation.[4] Improving

data availability and quality is crucial to monitor the reduction of LBW globally.

To accelerate the progress of LBW reduction, LBW could be specified as preterm, small for gestational age (SGA), or both on the basis of cause, as proposed by the *Lancet* Small Vulnerable Newborn Series team.[3] The number of preterm births was estimated at 13·4 million with a prevalence of 9·9% in 2020, with no downward trend from 9·8% in 2010.[5] Preterm births could contribute about two-thirds of LBW newborns,[6] with the other third possibly related to SGA births.[6] Additionally, older age at childbearing and medically assisted reproduction could increase the risk of LBW and preterm delivery.[7,8]

Maternal nutrition, infection, and environmental exposures contribute about half of preterm births and 39% of SGA births in low-income and middle-income countries (LMICs).[1] Maternal nutritional status has the greatest population-attributable fraction for SGA births in LMICs.[9] Adequate nutrition over the life course is crucial for a healthy pregnancy and delivery of a newborn with normal weight. However, maternal undernutrition remains a concern in low-income countries and among the poorest households in middle-income countries.[10] Supplementation with multiple micronutrients and balanced energy and protein supplements, and supplementation or fortification of foods with folic acid, could be fully implemented for undernourished pregnant women to decrease the risk of SGA and preterm births.[11,12] Maternal nutrition counselling during antenatal care is important for women to improve the quality of their diet. More studies into the effects of a healthy diet on SGA and preterm birth reduction are warranted to implement healthy diet interventions during pregnancy. Gestational weight gain is a valuable indicator for monitoring the health of a pregnancy; however, data on gestational weight gain are missing for many LMICs.[10] Identifying an ideal range for gestational weight gain will be necessary to minimise SGA and large-for-gestational-age births globally.

LBW reduction to achieve the 2030 target remains a great challenge for the global community. Strengthening the monitoring of LBW and implementing comprehensive interventions before and during pregnancy are crucial to accelerate LBW reduction.

We declare no competing interests.

Zhenyu Yang, Suying Chang
yangzy@ninh.chinacdc.cn

National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China (ZY); UNICEF China, Beijing, China (SC)

1   Ashorn P, Ashorn U, Muthiani Y, et al. Small vulnerable newborns—big potential for impact. *Lancet* 2023; **401:** 1692–706.
2   Okwaraji YB, Krasevec J, Bradley E, et al. National, regional, and global estimates of low birthweight in 2020, with trends from 2000: a systematic analysis. *Lancet* 2024; published online Feb 28. https://doi.org/10.1016/S0140-6736(23)01198-4.
3   Lawn JE, Ohuma EO, Bradley E, et al. Small babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting. *Lancet* 2023; **401:** 1707–19.
4   Shen L, Wang J, Duan Y, Yang Z. Prevalence of low birth weight and macrosomia estimates based on heaping adjustment method in China. *Sci Rep* 2021; **11:** 15016.
5   WHO, UN Population Fund, UNICEF, Partnership for Maternal, Newborn & Child Health. Born too soon: decade of action on preterm birth. May 9, 2023. https://www.who.int/publications/i/item/9789240073890 (accessed July 21, 2023).
6   Blencowe H, Krasevec J, de Onis M, et al. National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. *Lancet Glob Health* 2019; **7:** e849–60.
7   Collins J. Global epidemiology of multiple birth. *Reprod Biomed Online* 2007; **15** (suppl 3)**:** 45–52.
8   Goisis A, Remes H, Martikainen P, Klemetti R, Myrskylä M. Medically assisted reproduction and birth outcomes: a within-family analysis using Finnish population registers. *Lancet* 2019; **393:** 1225–32.
9   Gurung S, Tong HH, Bryce E, et al. A systematic review on estimating population attributable fraction for risk factors for small-for-gestational-age births in 81 low- and middle-income countries. *J Glob Health* 2022; **12:** 04024.
10   Victora CG, Christian P, Vidaletti LP, Gatica-Domínguez G, Menon P, Black RE. Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda. *Lancet* 2021; **397:** 1388–99.
11   Hunter PJ, Awoyemi T, Ayede AI, et al. Biological and pathological mechanisms leading to the birth of a small vulnerable newborn. *Lancet* 2023; **401:** 1720–32.
12   Hofmeyr GJ, Black RE, Rogozińska E, et al. Evidence-based antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes. *Lancet* 2023; **401:** 1733–44.

Making COP28 rhetoric a reality

The outcomes of the 28th Conference of the Parties UN Climate Change Conference (COP28) held in Dubai, United Arab Emirates, in December, 2023, have been welcomed by some commentators, notably for the launch of the Loss and Damage Fund, the first Health Day, the Declaration on Sustainable Agriculture, Resilient Food Systems and Climate Action, and the first inclusion of fossil fuels in the official negotiations.[1] Other commentators have argued that these steps, while important, are insufficient to tackle the climate crisis taking us beyond the 1·5°C global temperature commitment of the Paris Agreement.[1,2] Such critiques are instructive, but it is now crucial to focus on pathways forward to ensure that the promises made at COP28 become reality. We propose that to operationalise such promises, and in ways that advance planetary health equity, there is an urgent need for national regulations and international treaties centred on mitigation.

In the first COP Declaration on Climate and Health, signed by more than 120 countries at COP28, nation states committed to develop and implement policies to "maximize the health gains" and "prevent worsening health impacts", while also integrate health in climate policies.[3] Climate change mitigation is arguably the biggest preventive health action possible in this area.[4–6] Therefore, if countries included in their next nationally determined contributions

(NDCs), which set out the country targets to meet the objectives of the Paris Agreement and are due by the end of 2024, the development and implementation of mitigation policies focused on "transitioning away from fossil fuels" and "shifting […] to more sustainable (agricultural) production and consumption approaches", human health would vastly improve.[5,7,8]

In the Global Stocktake at COP28 (the negotiations outcome document that assessed the state of the commitments made with the Paris Agreement), countries committed to "transitioning away from fossil fuels in energy systems, in a just, orderly and equitable manner".[7] Equity, both within and between countries, must be at the centre of the development of these policies. However, prioritisation of profit in the current economic system has downgraded equity considerations, while creating power dynamics that increase inequities, with big corporations such as the fossil fuel industry having power over governments.[9] However, governments' actions, such as the removal of fossil fuel subsidies, can shift financial support from the polluters to the people, especially those most affected by pollution and climate change.[5] This additional public money could be invested in environmentally sustainable housing, jobs, and transport to help people transition to a life less dependent on fossil fuels. Internationally, a Fossil Fuel Non-Proliferation Treaty, currently supported by 12 nation states,[10] with Colombia,